Alpha‐Synuclein as a Biomarker for Parkinson's Disease

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Brain Pathology

• Publication date

  2016-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/bpa.12370PMID 26940058PMCID PMC6245641
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• [Parkinson's disease].

  2022cited by this paper
• MDS clinical diagnostic criteria for Parkinson's disease

  2015cited by this paper
• Detection of α-synuclein oligomers in red blood cells as a potential biomarker of Parkinson's disease.

  2015cited by this paper
• Total and Proteinase K-Resistant α-Synuclein Levels in Erythrocytes, Determined by their Ability to Bind Phospholipids, Associate with Parkinson’s Disease

  2015cited by this paper
• Phosphorylated α-synuclein in Parkinson’s disease: correlation depends on disease severity

  2015influential reference
• Cerebrospinal Fluid Lysosomal Enzymes and Alpha-Synuclein in Parkinson's Disease

  2014influential reference
• Saliva α-Synuclein and A High Extinction Coefficient Protein: A Novel Approach in Assessment Biomarkers of Parkinson's Disease

  2014cited by this paper
• Cheek cell-derived α-synuclein and DJ-1 do not differentiate Parkinson's disease from control.

  2014cited by this paper
• Plasma exosomal α-synuclein is likely CNS-derived and increased in Parkinson’s disease

  2014cited by this paper
• In Vitro Phosphorylation Does not Influence the Aggregation Kinetics of WT α-Synuclein in Contrast to Its Phosphorylation Mutants

  2014cited by this paper
• Skin nerve α-synuclein deposits

  2014cited by this paper
• Biomarkers of Parkinson's disease: current status and future perspectives.

  2013cited by this paper
• Submandibular gland biopsy for the diagnosis of Parkinson disease.

  2013cited by this paper
• CSF α-synuclein improves diagnostic and prognostic performance of CSF tau and Aβ in Alzheimer’s disease

  2013cited by this paper
• [Epidemiology of Parkinson's disease].

  2013cited by this paper
• Naturally occurring α-synuclein autoantibody levels are lower in patients with Parkinson disease

  2013cited by this paper
• Total CSF α-synuclein is lower in de novo Parkinson patients than in healthy subjects.

  2013influential reference
• Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease.

  2013influential reference
• Parkinson disease affects peripheral sensory nerves in the pharynx.

  2013cited by this paper
• Phosphorylated alpha-Synuclein in Parkinson's Disease

  2012influential reference
• Alpha-synuclein: from secretion to dysfunction and death

  2012cited by this paper
• Phosphorylated α-Synuclein in Parkinson’s Disease

  2012cited by this paper
• A comparison between rectal and colonic biopsies to detect Lewy pathology in Parkinson's disease.

  2012cited by this paper
• α-Synuclein Levels in Blood Plasma from LRRK2 Mutation Carriers

  2012cited by this paper
• Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders.

  2012cited by this paper
• α-Synuclein and Anti-α-Synuclein Antibodies in Parkinson’s Disease, Atypical Parkinson Syndromes, REM Sleep Behavior Disorder, and Healthy Controls

  2012cited by this paper
• Alpha‐synuclein in colonic submucosa in early untreated Parkinson's disease

  2012cited by this paper
• Neuropathology of sporadic Parkinson's disease: Evaluation and changes of concepts

  2012influential reference
• Alpha-Synuclein Posttranslational Modification and Alternative Splicing as a Trigger for Neurodegeneration

  2012cited by this paper
• Emerging Role of Neuronal Exosomes in the Central Nervous System

  2012cited by this paper
• Exosomal cell-to-cell transmission of alpha synuclein oligomers

  2012cited by this paper
• A comparison between colonic submucosa and mucosa to detect Lewy pathology in Parkinson’s disease

  2012cited by this paper
• α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.

  2011influential reference
• Elevated Levels of α-Synuclein Oligomer in the Cerebrospinal Fluid of Drug-Naïve Patients with Parkinson's Disease

  2011cited by this paper
• α-Synuclein Reactive Antibodies as Diagnostic Biomarkers in Blood Sera of Parkinson's Disease Patients

  2011cited by this paper
• Conserved C-terminal charge exerts a profound influence on the aggregation rate of α-synuclein.

  2011cited by this paper
• Phosphorylation of α-synuclein upregulates tyrosine hydroxylase activity in MN9D cells.

  2011influential reference
• Parkinson's disease: genetics and pathogenesis.

  2011cited by this paper
• Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies.

  2011cited by this paper
• Phosphorylated α‐synuclein can be detected in blood plasma and is potentially a useful biomarker for Parkinson's disease

  2011cited by this paper
• Authentically Phosphorylated α-Synuclein at Ser129 Accelerates Neurodegeneration in a Rat Model of Familial Parkinson's Disease

  2011cited by this paper
• Lysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmission

  2011cited by this paper
• Cerebrospinal fluid Tau/α‐synuclein ratio in Parkinson's disease and degenerative dementias

  2011influential reference
• Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression

  2011influential reference
• Pallidal stimulation in siblings with pantothenate kinase‐associated neurodegeneration: Four‐year follow‐up

  2011cited by this paper
• Salivary α-synuclein and DJ-1: potential biomarkers for Parkinson's disease.

  2011cited by this paper
• The epidemiology of dementia associated with Parkinson disease.

  2010cited by this paper
• Mild cognitive impairment in Parkinson's disease: subtypes and motor characteristics.

  2010cited by this paper
• Lewy pathology in the submandibular gland of individuals with incidental Lewy body disease and sporadic Parkinson’s disease

  2010cited by this paper
• Functional correlates of lower cognitive test scores in essential tremor

  2010influential reference
• Multi-organ distribution of phosphorylated α-synuclein histopathology in subjects with Lewy body disorders

  2010cited by this paper
• Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease

  2010cited by this paper
• Colonic Biopsies to Assess the Neuropathology of Parkinson's Disease and Its Relationship with Symptoms

  2010cited by this paper
• Role of post-translational modifications in modulating the structure, function and toxicity of alpha-synuclein: implications for Parkinson's disease pathogenesis and therapies.

  2010cited by this paper
• Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease.

  2010influential reference
• SNCA variant associated with Parkinson disease and plasma alpha-synuclein level.

  2010cited by this paper
• DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease.

  2010influential reference
• Diagnosis and the premotor phase of Parkinson disease

  2009cited by this paper
• &agr;-Synuclein S129 Phosphorylation Mutants Do Not Alter Nigrostriatal Toxicity in a Rat Model of Parkinson Disease

  2009cited by this paper
• Diminished tyrosine hydroxylase immunoreactivity in the cardiac conduction system and myocardium in Parkinson’s disease: an anatomical study

  2009cited by this paper
• Biopsies of olfactory epithelium in patients with Parkinson's disease

  2009cited by this paper
• Olfactory bulb α-synucleinopathy has high specificity and sensitivity for Lewy body disorders

  2009cited by this paper
• Cerebrospinal fluid a-synuclein in neurodegenerative disordersA marker of synapse loss?

  2009cited by this paper
• α-Synuclein gene duplication is present in sporadic Parkinson disease

  2008cited by this paper
• N‐terminal region of α‐synuclein is essential for the fatty acid‐induced oligomerization of the molecules

  2008cited by this paper
• Phosphorylation at Ser-129 but Not the Phosphomimics S129E/D Inhibits the Fibrillation of α-Synuclein*

  2008cited by this paper
• Phosphorylation does not prompt, nor prevent, the formation of alpha-synuclein toxic species in a rat model of Parkinson's disease.

  2008cited by this paper
• Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson's disease.

  2008cited by this paper
• Cardiac sympathetic denervation correlates with clinical and pathologic stages of Parkinson's disease

  2008cited by this paper
• α-Synuclein gene duplication is present in sporadic Parkinson disease

  2008cited by this paper
• Axonal α-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson's disease

  2008cited by this paper
• Pathological lesions in colonic biopsies during Parkinson’s disease

  2008cited by this paper
• Olfactory bulb α-synucleinopathy has high specificity and sensitivity for Lewy body disorders

  2008cited by this paper
• Red Blood Cells Are the Major Source of Alpha-Synuclein in Blood

  2008cited by this paper
• Parkinson's disease dementia: Definitions, guidelines, and research perspectives in diagnosis

  2008cited by this paper
• Plasma α-synuclein is decreased in subjects with Parkinson's disease

  2007cited by this paper
• Oxidative stress‐induced phosphorylation, degradation and aggregation of α‐synuclein are linked to upregulated CK2 and cathepsin D

  2007influential reference
• Neuropathology, biochemistry, and biophysics of α‐synuclein aggregation

  2007cited by this paper
• Expression of alpha-synuclein, a presynaptic protein implicated in Parkinson's disease, in erythropoietic lineage.

  2007cited by this paper
• Neuropathology, biochemistry, and biophysics of alpha-synuclein aggregation.

  2007cited by this paper
• Plasma alpha-synuclein is decreased in subjects with Parkinson's disease.

  2007cited by this paper
• Calpain-Cleavage of α-Synuclein : Connecting Proteolytic Processing to Disease-Linked Aggregation

  2007cited by this paper
• Clinical diagnostic criteria for dementia associated with Parkinson's disease

  2007cited by this paper
• Calpain-cleavage of alpha-synuclein: connecting proteolytic processing to disease-linked aggregation.

  2007cited by this paper
• Detection of oligomeric forms of α‐synuclein protein in human plasma as a potential biomarker for Parkinson's disease

  2006cited by this paper
• Alpha-synuclein pathology in the spinal cords of neurologically asymptomatic aged individuals.

  2006cited by this paper
• Decreased α-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson’s disease.

  2006cited by this paper
• Epidemiology of Parkinson's disease.

  2006cited by this paper
• Differences in neuropathologic characteristics across the Lewy body dementia spectrum

  2006cited by this paper
• Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology.

  2006cited by this paper
• Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease.

  2006influential reference
• The Role of G-Protein-Coupled Receptor Kinase 5 in Pathogenesis of Sporadic Parkinson's Disease

  2006influential reference
• α-Synuclein structure, posttranslational modification and alternative splicing as aggregation enhancers

  2006cited by this paper
• The plasma alpha-synuclein levels in patients with Parkinson’s disease and multiple system atrophy

  2006influential reference
• Excess burden of constipation in Parkinson's disease: A pilot study

  2006cited by this paper
• Skin and platelet α-synuclein as peripheral biomarkers of Parkinson's disease

  2005cited by this paper
• Alpha-synuclein phosphorylation enhances eosinophilic cytoplasmic inclusion formation in SH-SY5Y cells.

  2005influential reference
• Intravesicular Localization and Exocytosis of α-Synuclein and its Aggregates

  2005cited by this paper
• A systematic review of prevalence studies of dementia in Parkinson's disease

  2005cited by this paper
• Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations.

  2005cited by this paper

• Glial Cells as Key Mediators in the Pathophysiology of Neurodegenerative Diseases

  2026cites this paper
• [Selective neurodegeneration in patients with parkinson's disease].

  2026cites this paper
• Clinical Validation of α‐Synuclein in Salivary Extracellular Vesicles as a Biomarker for Parkinson's Disease: A Longitudinal Study

  2026cites this paper
• Evaluation of idiopathic olfactory dysfunction as a warning marker for early parkinson’s disease: a population-based cross-sectional study

  2026cites this paper
• Material-based neuroimaging and biomarker detection for central nervous system disorder

  2025cites this paper
• A Spatio-Temporal Fusion-Based Approach for Multi-Dimensional Classification of Parkinson’s Disease Progression Using Multi-Modal Dataset

  2025cites this paper
• Bioanalytical Considerations for Biomarkers of Parkinson's Disease

  2025cites this paper
• Propagation of pathologic α-synuclein from kidney to brain may contribute to Parkinson’s disease

  2025cites this paper
• Parkin characteristics and blood biomarkers of Parkinson’s disease in WPBLC study

  2025cites this paper
• Unveiling the Cutting Edge: Recent Developments in α-Synuclein Nano-biosensor Technology for Precision Diagnosis of Parkinson’s Disease

  2025cites this paper
• Unravelling the nexus of stroke and dementia: Deciphering the role of secondary neurodegeneration in orchestrating cognitive decline

  2025cites this paper
• A fragment of Calpain-1 cleaved α-Synuclein quantified in serum is upregulated in patients with Parkinson’s disease

  2025cites this paper
• In vitro electrophysiological characterization of Parkinson’s disease: challenges, advances, and future directions

  2025cites this paper
• Mesenchymal Stem Cell-Derived Extracellular Vesicles: Emerging Therapies for Neurodegenerative Diseases

  2025cites this paper
• Hybrid preprocessing and ensemble classification for enhanced detection of Parkinson's disease using multiple speech signal databases

  2025cites this paper
• Epigenetics in neurodegeneration: Emerging biomarkers and translational insights

  2025cites this paper
• A multi-dimensional study on taste deficits, α-synuclein genetic profiling, and supervised learning for diagnosis and disease severity stratification in Parkinson's disease (PD).

  2025cites this paper
• Advances in Aggrephagy: Mechanisms, Disease Implications, and Therapeutic Strategies

  2025cites this paper
• The Relationship Between Neuropsychiatric Disorders and the Oral Microbiome

  2025cites this paper
• Understanding the influence of TLR-Mediated Immune System on Necroptosis-Induced Neurodegeneration in Parkinson's Disease.

  2025cites this paper
• The role of aliphatic polyamines and α-synuclein in the formation of peripheral mechanisms involved in the Parkinson’s disease induction

  2025cites this paper
• Positron emission tomography tracers for synucleinopathies

  2025cites this paper
• Age-Dependent Effects of Paraquat-Induced Parkinsonism on Serum Alpha-Synuclein Expression, Substantia Nigra Histoarchitecture and Neurobehaviour in Male Wistar Rats

  2025cites this paper
• Protein regulatory network mediated by palmitoylation modifications in the pathological progression of Parkinson’s disease: a narrative review

  2025cites this paper
• Gpr35 Expression Mitigates Neuroinflammation and Enriches Gut Lactobacillus to Relieve Parkinson’s Disease

  2025cites this paper
• Early detection of Parkinson’s disease through multiplex blood and urine biomarkers prior to clinical diagnosis

  2025cites this paper
• α-Synuclein aggregates inhibit ESCRT-III through sequestration and collateral degradation.

  2025cites this paper
• Polymer-Based Electrochemical Sensors for the Diagnosis of Neurodegenerative Diseases

  2025cites this paper
• Early diagnosis of Parkinson's disease pathogenesis using biofluidic biomarkers with a focus on α-synuclein

  2025cites this paper
• Transmission Electron Microscopy-based characterization of Extracellular Vesicles from plasma and serum from Parkinson´s Disease patients

  2025cites this paper
• Cerebrospinal Fluid Biomarkers for Diagnosis of Parkinson’s disease: A Systematic Review

  2025cites this paper
• Gut Microbiome as a Source of Probiotic Drugs for Parkinson’s Disease

  2025cites this paper
• Toward a biological definition of neuronal and glial synucleinopathies

  2025cites this paper
• Regulation of mitochondrial dynamics and function by melatonin type 1 receptor in parkinson’s disease

  2025cites this paper
• Microfluidic platform for understanding Parkinson’s disease and α-synuclein conformation

  2025cites this paper
• Protocol for immunodetection of α-synuclein pathology in paraffin-embedded liver tissues from murine models of Parkinson’s disease

  2025cites this paper
• Regional homogeneity differences in resting-state fMRI between Parkinson’s disease and multiple system atrophy-parkinsonian type

  2025cites this paper
• Evolving Landscape of Parkinson’s Disease Research: Challenges and Perspectives

  2025cites this paper
• Association between air pollution and cerebrospinal fluid alpha-synuclein in urban elders: the CABLE study

  2024cites this paper
• THE LEVEL OF Α-SYNUCLEIN IN THE PLASMA AS A BIOMARKER OF PAIN IN PARKINSON'S DISEASE TAKING INTO ACCOUNT THE MOTOR SUBTYPES

  2024cites this paper
• How do HCN channels play a part in Alzheimer's and Parkinson's disease?

  2024cites this paper
• Experimental Parkinson Models and Green Chemistry Approach.

  2024cites this paper
• AIMP2 accumulation in brain leads to cognitive deficits and blood secretion in Parkinson’s disease

  2024cites this paper
• Exploring serum α‑synuclein and its autoantibodies in essential tremor: implications for diagnosis and symptom correlations

  2024cites this paper
• Extracellular vesicles as nanotheranostic platforms for targeted neurological disorder interventions

  2024cites this paper
• Potential Exosome Biomarkers for Parkinson’s Disease Diagnosis: A Systematic Review and Meta-Analysis

  2024cites this paper
• Exploring the Common Genes Involved in Autism Spectrum Disorder and Parkinson's Disease: A Systematic Review

  2024cites this paper
• 4-Oxo-2-Nonenal- and Agitation-Induced Aggregates of α-Synuclein and Phosphorylated α-Synuclein with Distinct Biophysical Properties and Biomedical Applications

  2024cites this paper
• Autophagy‐associated non‐coding RNAs: Unraveling their impact on Parkinson's disease pathogenesis

  2024cites this paper
• Combined diagnosis for Parkinson's disease via gait and eye movement disorders.

  2024cites this paper
• A binding-triggered hybridization chain reaction cascade multi-site activated CRISPR/Cas12a signal amplification strategy for sensitive detection of α-synuclein.

  2024cites this paper
• Microglial Exosomes in Paraquat-Induced Parkinson's Disease: Neuroprotection and Biomarker Clues.

  2024cites this paper
• The Synergistic Effect Study of Lipopolysaccharide (LPS) and A53T-α-Synuclein: Intranasal LPS Exposure on the A53T-α-Synuclein Transgenic Mouse Model of Parkinson’s Disease

  2024cites this paper
• Pathological α-synuclein detected by real-time quaking-induced conversion in synucleinopathies.

  2024cites this paper
• An innovative transportable immune device for the recognition of α-synuclein using KCC-1-nPr-CS2 modified silver nano-ink: integration of pen-on-paper technology with biosensing toward early-stage diagnosis of Parkinson's disease

  2024cites this paper
• Integrated network pharmacology and phosphoproteomic analyses of Baichanting in Parkinson's disease model mice

  2024cites this paper
• Therapeutic potential of Coumarin-polyphenolic acid hybrids in PD: inhibition of α-Syn aggregation and disaggregation of preformed fibrils, leading to reduced neuronal inclusion formation.

  2024cites this paper
• Detection of elevated levels of PINK1 in plasma from patients with idiopathic Parkinson’s disease

  2024cites this paper
• Potential Convergence of Olfactory Dysfunction in Parkinson's Disease and COVID-19: The Role of Neuroinflammation.

  2024cites this paper
• Passive immunotherapy for Alzheimer's disease.

  2024cites this paper
• In vitro modulation of mTOR and mGlur5 influence α-synuclein accumulation

  2024cites this paper
• Cognitive disorders: potential astrocyte-based mechanism.

  2024cites this paper
• Role and Diagnostic Significance of Apolipoprotein D in Selected Neurodegenerative Disorders

  2024cites this paper
• Small Molecules in Parkinson’s Disease Therapy: From Dopamine Pathways to New Emerging Targets

  2024cites this paper
• Neuroinflammation as an Integral Component of Neurodegeneration in Parkinson's Disease

  2024cites this paper
• Exploring α-synuclein Interaction Partners and their Potential Clinical Implications for Parkinson’s Disease

  2024cites this paper
• Isorhamnetin Ameliorates Dopaminergic Neuronal Damage via Targeting FOSL1 to Activate AKT/mTOR in 6-OHDA-induced SH-SY5Y Cells.

  2024cites this paper
• Accumulation of alpha-synuclein pathology in the liver exhibits post-translational modifications associated with Parkinson’s disease

  2024cites this paper
• Eye movement disorders: A new approach to preliminary screening of Parkinson's disease.

  2024cites this paper
• Correlations among serum alpha-(1,6)-fucosyltransferase and early symptoms associated with Parkinson's disease: A cross-sectional retrospective study.

  2024cites this paper
• Exploring and Validating Key Genetic Biomarkers for Diagnosis of Parkinson's Disease.

  2024cites this paper
• Advances of curcumin in nervous system diseases: the effect of regulating oxidative stress and clinical studies

  2024cites this paper
• Combined measure of salivary alpha-synuclein species as diagnostic biomarker for Parkinson’s disease

  2023cites this paper
• Erythrocytic alpha-synuclein as potential biomarker for the differentiation between essential tremor and Parkinson’s disease

  2023cites this paper
• Synucleinopathies: Intrinsic and Extrinsic Factors

  2023cites this paper
• α-Synuclein Strains and Their Relevance to Parkinson’s Disease, Multiple System Atrophy, and Dementia with Lewy Bodies

  2023cites this paper
• Meta-analysis to Implement Alpha-Synuclein in Extracellular Vesicles as a Potential Biomarker for Parkinsons Disease.

  2023cites this paper
• Targeting α-synuclein aggregation with immunotherapy: a promising therapeutic approach for Parkinson’s disease

  2023cites this paper
• Noradrenergic neuromodulation in ageing and disease.

  2023cites this paper
• Alpha-synuclein in skin as a high-quality biomarker for Parkinson's disease.

  2023cites this paper
• Peculiarities of some candidate gene polymorphisms in Parkinson’s disease

  2023cites this paper
• Development of a hydroxyflavone-labelled 4554W peptide probe for monitoring αS aggregation

  2023cites this paper
• Cerebrospinal fluid and blood serum biomarkers in neurodegenerative proteinopathies: A prospective, open, cross‐correlation study

  2023cites this paper
• Serum and Exosomal miR-7-1-5p and miR-223-3p as Possible Biomarkers for Parkinson’s Disease

  2023cites this paper
• Distribution and synaptic organization of substance P-like immunoreactive neurons in the mouse retina

  2023cites this paper
• Cognitive heterogeneity in Parkinson's disease: A mechanistic view.

  2023cites this paper
• The cervical lymph node contributes to peripheral inflammation related to Parkinson’s disease

  2023cites this paper
• Fluid Biomarkers for the Diagnosis of Neurodegenerative Diseases

  2023cites this paper
• Postural control of Parkinson’s disease: A visualized analysis based on Citespace knowledge graph

  2023cites this paper
• Redox Imbalance in Neurological Disorders in Adults and Children

  2023cites this paper
• Salivary Exosomes in Health and Disease: Future Prospects in the Eye

  2023cites this paper
• Decreased serum levels of α‐synuclein in patients with schizophrenia and their unaffected siblings

  2023cites this paper
• NLRP3 Inflammasome-Mediated Neuroinflammation and Related Mitochondrial Impairment in Parkinson’s Disease

  2023cites this paper
• Vitamin B6, B12 and folate modulate deregulated pathways and protein aggregation in yeast model of Huntington disease

  2023cites this paper
• Seed amplification assay for the detection of pathologic alpha-synuclein aggregates in cerebrospinal fluid

  2023cites this paper
• One-Pot Radiosynthesis of [18F]Anle138b—5-(3-Bromophenyl)-3-(6-[18F]fluorobenzo[d][1,3]dioxol-5-yl)-1H-pyrazole—A Potential PET Radiotracer Targeting α-Synuclein Aggregates

  2023cites this paper
• Rapid Scan Electron Paramagnetic Resonance Spectroscopy Is a Suitable Tool to Study Intermolecular Interactions of Intrinsically Disordered Protein

  2023cites this paper
• Neuronal Vulnerability to Degeneration in Parkinson's Disease and Therapeutic Approaches.

  2023cites this paper
• Mendelian Randomization Analysis Reveals No Causal Relationship Between Plasma α-Synuclein and Parkinson’s Disease

  2023cites this paper
• Application of serum peptidomics for Parkinson's disease in SNCA-A30P mice

  2023cites this paper